P.I.: EP PerMed Pharmacogenomic strategies for personalised medicine approaches (PGxPM2025)
PGxPM2025
Fecha cierre - 18/02/2025
Descripción Convocatoria
Joint Transnational Call for Proposals (2025) for Pharmacogenomic strategies for personalised medicine approaches (PGxPM2025)
Web: https://www.eppermed.eu/funding-projects/calls/jtc2025/
Fechas importantes:
09 January 2025 JTC2025 information day (Recordings available)
Plazo oficial: Submission of pre-proposals: 18/02/2025
Plazo interno: 16/02/2025 (Después de este plazo, seguimos trabajando pero no podemos asegurar solventar los posibles fallos o problemas con las plataformas de solicitud).
Financiación: convocatoria internacional con financiación nacional
-ISCIII:
Spanish Partner is NOT the Coordinator:
- 220.000 € (overheads included), if there is only one Spanish Partner requesting funding to the ISCIII in the proposal
- 275.000 € (overheads included), if there are two Spanish Partners requesting funding to the ISCIII in the proposal.
Spanish Partner IS the Coordinator:
- 300.000 € (overheads included), if there is only one Spanish Partner in the proposal, acting as a coordinator.
- 400.000 € (overheads included), if there is one Spanish Partner in addition to the Spanish Coordinator in the proposal, both requesting funding to the ISCIII.
-CSCJA:
Spanish Partner is NOT the Coordinator: 125.000€ (overheads included)
Spanish Partner IS the Coordinator: 250.000€ (overheads included)
Objetivo de la convocatoria:
With this call, EP PerMed will fund research projects in human health on pharmacogenomic strategies for PM approaches that address one or m ore of the following aspects:
- identification of new pharmacogenomic markers or signatures using (multi)-omics data in re-lation to drug or drug combination.
- validation of a pharmacogenomic marker or signatures using (multi)-omics data in predicting drug or drug combination outcomes.
- use pharmaco-omics strategies to determine the right dosage, the efficacy of treatments and/or the risk of adverse drug response and non-response to treatment to tailor personalised treatment pathways, including combined treatments (multi-medication).
Criterios de elegibilidad del consorcio:
Only transnational projects will be funded.
- Each consortium must involve at least three partners from three different EU Member States or Associated Countries5 whose funding organisations participate in the call (see list above)6. Each of these partners must be eligible and request funding from the respec-tive funding organisation. All three legal entities must be independent of each other.
- The project coordinator (i.e. the principal investigator and the applicant’s organisation) must be eligible to be funded by his/her regional/national participating funding organisa-tion. The project coordinator (i.e. principal investigator and organisation) cannot be changed between the first and second stage.
Max. 2 project partners per consortium can request funding from the same funding or-ganisation.
No more than one partner with their own funding is allowed in the consortia with at least three partners eligible for funding
Within one consortium, no more than 2 partners can request funding from the same funding organisation, including patient/citizen organisations.
Widening concept7: Consortia are allowed to include in the full-proposal phase an addi-tional project partner that is eligible to receive funding from a funding organisation that is underrepresented in the second stage of the call and that agrees to participate in the widening option
Additional eligibility criteria: revisar Guidelines for Applicants
Duración del proyecto: A maximum project duration of 3 years
Plataforma de solicitud: https://ptoutline.eu/app/EPPERMED2025
DOCUMENTOS CONVOCATORIA
